Preoperative glucose levels may predict postoperative cardiac outcomes regardless of whether patients have diabetes
For patients without diabetes, predictors of myocardial injury after noncardiac surgery included a casual glucose level of more than 6.86 mmol/L (124 mg/dL) and a fasting glucose level of more than 6.41 mmol/L (116 mg/dL).
Patients on the intermittent energy restriction diet ate 500 to 600 kcal/d on two nonconsecutive days each week and followed their usual diet on the other days. They were compared to a group eating 1,200 to 1,500 kcal/d.
Basal insulin analogs and NPH insulin had similar rates of hypoglycemia hospital visits, glycemic control in type 2 diabetes
Researchers used data from Kaiser Permanente of Northern California to retrospectively assess patients with type 2 diabetes who initiated a long-acting insulin analog or NPH insulin between Jan. 1, 2006, and Sept. 30, 2015.
SGLT2 inhibitors, GLP-1 agonists associated with lower mortality compared to DPP-4 inhibitors, analysis finds
Glucagon-like peptide-1 (GLP-1) agonists were associated with a higher risk of adverse events than sodium-glucose cotransporter-2 (SGLT2) inhibitors or dipeptidyl peptidase 4 (DPP-4) inhibitors, according to the meta-analysis.
The results highlight the importance of psychosocial interventions for at-risk patients, they concluded.
Study finds potential early indicators of myocardial dysfunction in asymptomatic elderly patients with type 2 diabetes
Researchers examined asymptomatic patients 65 years of age and older with type 2 diabetes and preserved left ventricular ejection fraction to look for impaired global longitudinal strain, diastolic dysfunction, or left atrial enlargement.
Patients with diabetes who were taking any beta-blocker, a beta-1 selective beta-blocker, or a specific beta-blocker had significantly higher risk for all-cause mortality versus patients with diabetes who were not taking a beta-blocker.
Between 2007 and 2014, more Medicare beneficiaries were newly prescribed metformin, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors, while fewer received long-acting sulfonylureas or thiazolidinediones.
The retrospective study at a single tertiary care referral medical center compared cost-effectiveness of care from a specialized diabetes team with care from a primary service team.
Review: Evidence is inconclusive on metabolic surgery vs. medical treatment for microvascular complications in T2DM
They also highlight the need for further RCTs assessing the effect of metabolic surgery on microvascular diabetes outcomes.